QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 assembly-biosciences-files-prospectus-relates-to-offering-resale-from-time-to-time-of-up-to-698m-shares-by-selling-stockholder

- SEC Filing

 hc-wainwright--co-reiterates-buy-on-assembly-biosciences-maintains-50-price-target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Assembly Biosciences (NASDAQ:ASMB) with a Buy and maintains $...

 4-biotechnology-stocks-that-outshine-in-momentum-amid-strong-technicals

Four biotechnology stocks have surged into the top 10th percentile for momentum ranking, demonstrating remarkable week-on-week ...

 jmp-securities-initiates-coverage-on-assembly-biosciences-with-market-outperform-rating-announces-price-target-of-38

JMP Securities analyst Roy Buchanan initiates coverage on Assembly Biosciences (NASDAQ:ASMB) with a Market Outperform rating...

 guggenheim-maintains-buy-on-assembly-biosciences-raises-price-target-to-39

Guggenheim analyst Vamil Divan maintains Assembly Biosciences (NASDAQ:ASMB) with a Buy and raises the price target from $31 ...

 hc-wainwright--co-assumes-assembly-biosciences-at-buy-announces-price-target-of-50

HC Wainwright & Co. analyst Patrick Trucchio assumes Assembly Biosciences (NASDAQ:ASMB) with a Buy rating and announces ...

 assembly-biosciences-announced-interim-data-from-several-cohorts-from-the-ongoing-phase-1a-trial-of-abi-6250-for-hepatitis-delta-virus

Data to date in single- and multiple-ascending dose cohorts of healthy participants demonstrate a four-day half-life for ABI-62...

 reported-saturday-assembly-biosciences-presents-phase-1a-and-preclinical-data-for-abi-5366-and-abi-1179-herpes-candidates-at-sti--hiv-2025-and-international-herpesvirus-workshop

– Phase 1a clinical data in healthy participants presented for both ABI-5366 and ABI-1179, novel long-acting herpes simplex vir...

 assembly-biosciences-announces-topline-results-from-its-phase-1b-clinical-trial-of-next-generation-investigational-capsid-assembly-modulator-abi-4334-in-chronic-hepatitis-b

– Favorable safety and tolerability profile, as well as pharmacokinetics supporting once-daily oral dosing, continued to be obs...

 syndeio-biosciences-launches-to-pioneer-precision-neurotherapeutics-focused-on-repairing-and-enhancing-synaptic-function-in-central-nervous-system-diseases

Clinical portfolio, informed by deep and novel synapse biology and pharmacology insights, aims to strengthen neural connections...

 assembly-biosciences-q1-eps-117-beats-160-estimate-sales-942m-beat-763m-estimate

Assembly Biosciences (NASDAQ:ASMB) reported quarterly losses of $(1.17) per share which beat the analyst consensus estimate of ...

 assembly-biosciences-releases-new-preclinical-date-for-oral-hepatitis-d-virus-entry-inhibitor-abi-6250-and-next-generation-hepatitis-b-virus-capsid-assembly-modulator-abi-4334-at-the-easl-congress-2025-in-amsterdam

– Late-breaker poster highlights preclinical profile of ABI-6250, currently in Phase 1a with data anticipated in Q3 2025 –– Sec...

 assembly-biosciences-unveils-data-on-long-acting-hsv-candidate-abi-5366-and-us-genital-herpes-trends-at-2025-escmid-congress

– Clinical and preclinical data supporting dosing profile and tolerability for ABI-5366, a novel long-acting helicase-primase i...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION